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Uveal melanoma is the most common primary ocular mali-
gnancy in adults. Typically, uveal melanoma can be diagnosed 
with non-invasive methods (dilated fundus exam, A- and B-mode 
ultrasound). In selected cases of atypical presentations, a biop-
sy becomes necessary (1–5).
Despite effective treatment methods available nowadays, 
there is always a risk of systemic metastases. The 25-year 
cumulative mortality associated with uveal melanoma is about 
52% for medium-size tumours (1, 6, 7). Most researchers con-
firm the presence of melanoma micrometastases at the time 
of diagnosis. Micrometastases can remain as stand-alone se-
quelae of melanoma or precede systemic, most commonly liver, 
metastases (1). The following are known as factors predispo-
sing to systemic metastases: larger diameter of a tumour base, 
tumour location in the cilliary body, epithelioid cell type mela-
noma, extraocular extension of melanoma, its vascular closed-
-loop system, chromosomal abnormalities and recurrence (8). 
Histopathology, cytogenetic, and gene expression patterns can 
facilitate prediction of systemic metastases (1, 9–13).
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Summary: Uveal melanoma can be typically diagnosed based on clinical presentation and the A and B mode ultrasound. In some atypical 
intraocular tumours or for prognostic purposes intraoperative biopsy may be performed. Uveal melanoma biopsy is not safe 
in 100% and can cause complications (vitreous hemorrhage, retinal detachment and endophthalmitis). Like all biopsies, a biop-
sy in uveal melanoma biopsy may show limited cellularity and can yield insufficient tissue specimen for histology, cytology 
and genetic testing. This is most likely in small tumours, below 3 mm in thickness. Another limitation of biopsy-based prognosis 
is the issue of intratumoural heterogeneity. As a biopsy allows for only a small sample to be removed from the tumour, it is po-
ssible to receive false negative results. The most devastating complication of uveal melanoma biopsy is the extraocular spread 
of the tumour.
 The study is a review of the current opinions and findings on the role of biopsy in uveal melanoma.
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Streszczenie: Diagnostyka czerniaka błony naczyniowej może być wykonana za pomocą różnych metod. Najczęściej do postawienia rozpo-
znania wystarczą standardowe metody diagnostyczne (badania dna oka oraz ultrasonografii w projekcji A i B). W niektórych 
przypadkach nietypowych guzów lub w celach prognostycznych konieczne staje się wykonanie biopsji guza wewnątrzgałko-
wego. Przeprowadzając biopsję, należy pamiętać o tym, że nie jest to metoda 100-procentowo bezpieczna i może zagrażać 
powikłaniami takimi jak krwawienie do ciała szklistego, odwarstwienie siatkówki i zapalenie wnętrza gałki ocznej. Podobnie jak 
w przypadku biopsji innych narządów, również pobierając materiał z czerniaka błony naczyniowej, należy się liczyć z pobraniem 
niewystarczającej ilości materiału do badań histopatologicznych, cytologicznych lub genetycznych. Ma to miejsce zwłaszcza 
w przypadku guzów o grubości mniejszej niż 3,0 mm. Wykonując biopsję, należy również wziąć pod uwagę niejednorodność 
tkanki guza – jeśli zostanie pobrana niewłaściwa tkanka, wynik będzie fałszywie ujemny. Największym niebezpieczeństwem 
związanym z wykonywaniem biopsji guzów wewnątrzgałkowych podejrzanych o czerniaka błony naczyniowej jest możliwość 
rozsiewu komórek nowotworowych.
 Celem pracy jest przedstawienie aktualnych poglądów na temat biopsji czerniaka błony naczyniowej.
Słowa kluczowe: czerniak błony naczyniowej, biopsja, monosomia chromosomu 3.
PRACE POGLĄDOWE
Uveal melanoma biopsy is performed for prognostic purpo-
ses, in order to detect chromosomal abnormalities associated 
with the high risk of metastases (most commonly chromoso-
me 3 monosomy), for diagnostic purposes (usually in 1–2% 
of diagnosed intraocular tumours), and in patients, who refuse 
therapy for uveal melanoma without prior histopathological ve-
rification (1–5, 14). If a biopsy is considered, it is necessary to 
analyze its likely prognostic and diagnostic outcomes as well 
as the risk of tumour cell spread, complications, and potential 
false negative result. In posteriorly located tumours, a biopsy is 
performed using transvitreal approach through the pars plana, 
while in patients with cilliary body and anterior choroidal tumo-
urs, it is performed by transscleral approach (1, 4, 10). The fine-
-needle aspiration biopsy (FNAB) is the most frequently used 
biopsy technique in uveal melanomas (4, 10, 14, 15).
In uveal melanoma, chromosomal abnormalities detected 
during the prognostic biopsy correlate with the risk of meta-
stases. The alterations most commonly affect chromosome 
3, 6q, 8p, 11q,13, and 1p (11, 16–22). The detection of mo-
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nosomy 3 found in almost 50% of uveal melanoma patients 
is of the highest prognostic value (1, 16–24). It is associated 
with the high risk of metastases-related death. Survival ana-
lyses in the monosomy 3 patients showed 50–70% mortality 
in this group in the four-year period since the beginning of the-
rapy (12, 13). Complete monosomy 3 is linked to worse survival 
prognosis, as compared to the partial monosomy 3 or disomy 
for chromosome 3 (20). Similarly, gain of chromosomal region 
8q, loss of 6q, loss of 1q and lack of BAP1 expression correlate 
with less favourable prognosis. However, gain of chromosome 
6p and EIF1AX expression are associated with better prognosis 
(11, 17, 18, 25–27).
Another means to assess the risk of metastatic disease in pa-
tients with uveal melanoma is gene expression profiling (GEP), 
which simultaneously measures the expression of several (about 
12) tumour genes (1, 9–11, 18). The risk of systemic metastases 
is low in GEP class 1 tumours and high in GEP class 2 tumours 
(1, 9–11). The five-year risk of developing systemic metastases 
is only 2% in class 1A tumours, 21% in class 1B tumours, re-
aching 72% in GEP class 2 tumours (28). However, the detection 
of monosomy 3, which occurs in about 10% of GEP class 1 tu-
mours is linked to an increased risk of systemic metastases (1).
The results of a prognostic biopsy in patients with uveal 
melanoma are used for care planning, including diagnostic ima-
ging to detect systemic metastases. In patients with low risk 
of systemic metastases, abdominal ultrasound and CT should 
be performed at least once a year, whereas in high risk pa-
tients, liver function assays are recommended every 3, 4 up to 
6 months, and imaging tests every 3–6 months (9).
According to the literature, 66–97% of biopsies yield po-
sitive result, confirming uveal melanoma (2, 3, 5, 7, 15, 29). 
The numeric discrepancy can be attributed to the insufficient 
biopsy aspirates as well as cytogenetic and histological hete-
rogeneity of the tumour (1, 4, 10, 15, 29–33). Insufficient biop-
sy samples for cytological examination were obtained through 
pars plana vitrectomy in 3–29% of patients and by transscleral 
approach in 29–44% of cases (3, 7, 10, 30).
Cumulative 5-year probability of death from metastasis was 
14.1 % for patients whose biopsy aspirates were insufficient for 
cytology-based classification versus 22.4 % for patients whose 
biopsy aspirates were sufficient for cytology-based classifica-
tion (10). When assessed in terms of GEP classification, tho-
ugh, it was 8% in cases where biopsy samples were insufficient 
for GEP classification or in GEP class 1 tumours, as compared 
to 45% in GEP class 2 tumours (10). It should be noted that for 
cytology evaluation, bigger tumour tissue samples are required, 
as compared to GEP classification purposes (2, 10).
Some researchers attempted to relate biopsy feasibility (ob-
taining positive result) to tumour size. Augsburger et al., Cohen 
et al., and Chang et al. reported a correlation between a positive 
result of a biopsy and tumour thickness in 37.5–64.7% of tumo-
urs thinner than 3.0 mm, in 75–92% of tumours 3.0–5.0 mm 
thick, and in 90–100% for tumour thicker than 5.0 mm (2, 3).
Another issue significantly affecting biopsy findings is tu-
mour heterogeneity. Percentage distribution of spindle and epi-
thelioid cells in tumour zones differs. Similarly, the percentage 
of chromosomal abnormalities, i.e. chromosome 3 monosomy 
or disomy, may vary (1, 7, 32). Higher rates of monosomy 3 
are more likely to occur in large-size tumours (31). The survival 
prognosis is worse in the patients with detected 33% of mono-
somy 3 cells (31). Tumour heterogeneity for monosomy of chro-
mosome 3 affects 14–18% of patients with uveal melanoma (1). 
Thus, it is possible to collect biopsy aspirates from the tumour 
zone without chromosomal abnormalities, which normally indi-
cate high risk of systemic metastases.
The question should be asked about the most appropriate tu-
mour site for drawing representative biopsy sample. Killgaard J. 
et al. demonstrated in their research a 58–59% chance for obta-
ining most representative samples from the central portions of 
tumours. The chance for obtaining representative samples from 
the periphery, top or tumour base was only 43–57% (34). It is 
therefore reasonable to aspirate more than 1 sample (usually 
2–12 samples) during a single biopsy (1, 7).
The obtained biopsy result can be false negative. However, 
even a negative result cannot completely exclude the presen-
ce tumour cells (4, 33). Ideally, an experienced pathologist 
should be present in the treatment room to immediately asses 
the quan tity and quality of the obtained aspirate, so as to ensu-
re the reliability of a biopsy (4).
When referring the patient for biopsy it is always necessary 
to consider its potential complications. These may include vi-
treous hemorrhage which occurs in 21–46% of patients, more 
commonly when 22G needles are used for aspiration. Usually, 
vitreous hemorrhage spontaneously resolves after some time 
(1, 3, 4, 7, 15). Retinal detachment occurring more frequently 
during pars plana vitrectomy biopsy may lead in some cases to 
retinal holes just above the lesion. The risk of retinal detachment 
is lower in small-size posterior tumours with a small amount 
of subretinal fluid. It increases in large-size tumours, containing 
more subretinal fluid. Retinal detachment is a rare complica-
tion of a biopsy performed through the transscleral appro ach, 
and the rates are even lower for the large-size tumours (4). 
Another very rare complication of a biopsy is uveitis. There are 
only two reports of uveitis as a complication of biopsy. Cohen 
et al. reported 2 cases of uveitis in a series of 83 performed 
biopsies, and Faulkner-Jones et al. reported 1 case in their se-
ries of 33 performed biopsies (4, 6).
The most serious biopsy complication in uveal melanoma 
is intraoperative extraocular tumour spread, which may pre-
sent either as extraocular extension or as systemic metastasis. 
The extraocular tumour spread may occur along the aspiration 
track at the site of sclerectomy (3, 4, 6, 15). The risk of tu-
mour spread is lower when a patient receives brachytherapy. 
It is also less likely in biopsies performed during the pars plana 
vitrectomy (3, 4).
In 2013, four cases of extraocular spread of uveal melano-
ma to the orbit were reported as a complication of a biopsy. 
In three of these patients, more than one biopsy was performed 
and 1 patient did not receive brachytherapy (35). The majority 
of patients undergoing biopsy (83–159) did not develop extra-
ocular recurrence of uveal melanoma (3, 4, 10, 15).
The risk of tumour spread during FNAB is scarce, but cannot 
be eliminated (4). Until now, there has been no report of syste-
mic metastases as a complication of a biopsy. It is believed 
that 25–27G may lower the risk of tumour spread in patients 
with uveal melanoma (4, 6).
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FNAB of uveal melanoma is becoming one of the main pro-
gnostic examinations. Despite all advantages of a biopsy, its 
limitations (tumour heterogeneity, obtaining non-representati-
ve sample) and complications should be always considered on 
a case basis.
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